The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies

There is an increasing interest in the neural effects of psychoactive drugs, in particular tryptamine psychedelics, which has been incremented by the proposal that they have potential therapeutic benefits, based on their molecular mimicry of serotonin. It is widely believed that they act mainly through 5HT2A receptors but their effects on neural activation of distinct brain systems are not fully understood. We performed a quantitative meta-analysis of brain imaging studies to investigate the effects of substances within this class (e.g., LSD, Psilocybin, DMT, Ayahuasca) in the brain from a molecular and functional point of view. We investigated the question whether the changes in activation patterns and connectivity map into regions with larger 5HT1A/5HT2A receptor binding, as expected from indolaemine hallucinogens (in spite of the often reported emphasis only on 5HT2AR). We did indeed find that regions with changed connectivity and/or activation patterns match regions with high density of 5HT2A receptors, namely visual BA19, visual fusiform regions in BA37, dorsal anterior and posterior cingulate cortex, medial prefrontal cortex, and regions involved in theory of mind such as the surpramarginal gyrus, and temporal cortex (rich in 5HT1A receptors). However, we also found relevant patterns in other brain regions such as dorsolateral prefrontal cortex. Moreover, many of the above-mentioned regions also have a significant density of both 5HT1A/5HT2A receptors, and available PET studies on the effects of psychedelics on receptor occupancy are still quite scarce, precluding a metanalytic approach. Finally, we found a robust neuromodulatory effect in the right amygdala. In sum, the available evidence points towards strong neuromodulatory effects of tryptamine psychedelics in key brain regions involved in mental imagery, theory of mind and affective regulation, pointing to potential therapeutic applications of this class of substances.


INTRODUCTION
Pharmacologic challenges with tryptamine hallucinogen substances have been used as models for psychosis. In recent years, many studies have used substances to study the neuronal correlates of altered states of consciousness (dos . A current research trend involves testing the effects of hallucinogens as potential therapeutic alternatives for psychiatric disorders (Kraehenmann, 2017;Lowe et al., 2021). Here we aimed to perform a quantitative meta-analysis of neuroimaging studies in this field. The current work summarizes the level of (in) consistency between functional imaging outcomes from connectivity and activation studies that might help to further clarify the implication of previous reports and their importance concerning the therapeutic potential of these drugs.
The relation between psychedelic experience and psychosis remains intriguing (Cumming et al., 2021). Sensory hallucinations and attentional deficits are common manifestations in schizophrenia and other neuropsychiatric disorders. The neural correlates of visual and auditory alertness in these conditions have been a matter of study. The approach of experimentally inducing states of psychosis was proven to be very useful to understand the effects of distinct substances in the brain in the so-called pharmacological fMRI approach (Daumann et al., 2010). In particular, neuroimaging studies have investigated the neural correlates of alertness based on agonistic modulation of the human serotonin 2A receptor (5-HT2AR, 5-hydroxytryptamine2A) (using dimethyltryptamine-DMT) and N-methyl-D-aspartic acid (NMDA) antagonism (using ketamine) for psychosis (Daumann et al., 2010). Moreover, 5-HT2AR activation through LSD has been implicated in the formation of visual hallucinations and cognitive impairments (Schmidt et al., 2018). The psychedelic experience produced by psilocybin (Psi) (a substance found in "magic mushrooms") is characterized by "unconstrained" cognition and profound alterations in the perception of time, space and selfhood . This substance is a preferential serotonin (5-HT) 2A/1A receptor agonist (Halberstadt and Geyer, 2011). Psilocybin, reduces the processing of negative stimuli  which is relevant concerning affective processing in the amygdala. This emotion-processing structure is particularly prone to serotonergic modulation. Psilocybin-induced decrease in amygdala reactivity correlates with and reduces threat-induced modulation of amygdala activation and/or connectivity (Kraehenmann et al., 2015Preller et al., 2017;Barrett et al., 2020b).
Other hallucinogens inducing similar effects have been used to study the rapid changes in brain dynamics and functional connectivity (FC) in neuroimaging, regarding the quality of conscious experience in the psychedelic state (Tagliazucchi et al., 2014, Tagliazucchi et al., 2016Luppi et al., 2021). These substances include Lysergic acid diethylamide (LSD) that induces profound changes across various mental domains, including perception, self-awareness and emotional state (Mueller et al., 2017;Luppi et al., 2021); or Ayahuasca, that is a beverage traditionally used by Amazonian Amerindians composed by a mixture of compounds that increase monoaminergic transmission. Ayahuasca caused significant decreases in the activity and connectivity of the default mode network (DMN) (Palhano-Fontes et al., 2015) and increased excitability in multimodal brain areas as the posterior association cortex, the cingulate, and the Medial temporal lobe (MTL) (Riba et al., 2004, Riba et al., 2006, that are pivotal in interoception and emotional processing. Psychedelic drugs such as LSD were used extensively in psychiatry in the past and their therapeutic potential is beginning to be re-examined today Kraehenmann, 2017). Accordingly, the use of these substances may have important implications for the treatment of depression, mood and anxiety disorders (Kraehenmann et al., 2015). Additionally, the current literature also emphasizes the importance of 5-HT2A/1A receptor subtypes in the control of social functioning, and as prospective targets in the treatment of sociocognitive impairments in psychiatric illnesses . Here we provide a comprehensive review of studies in this field. Our findings suggest important implications for the understanding of the mechanism of action of hallucinogenic drugs and provide further insight into the role of these substances to improve mental health, pain or neurodegenerative disorders.

Search Strategy and Data Sources
We performed the literature search using the PubMed database in Sep/2020. The search criteria were: LSD (Title/Abstract) OR lysergic (Title/Abstract) OR psilocybin (Title/Abstract) OR ayahuasca (Title/Abstract) OR dimethyltryptamine (Title/ Abstract) AND [fMRI (Title/Abstract) OR BOLD (Title/ Abstract) OR PET (Title/Abstract)]. Figure 1 (PRISMA) summarizes the number of articles and duplicates that were found. To identify functional brain imaging studies, our inclusion criteria were: 1) the studies imaged the whole brain; 2) the results presented coordinate-based data in a standard space and were not review papers; 3) the imaging method was fMRI or PET; 4) subjects were healthy controls; 5) sample size N ≥ 8 (Eickhoff et al., 2016).
From the initial identification of 78 studies, the final study included 16 fMRI studies and four PET studies (Table 1) reporting brain imaging experiments related to those drugs. We then used the foci of brain activations extracted from each of the included studies for the ALE analysis.

Data Extraction
We exported foci data manually from each paper to a text file containing all the coordinates of the results from the original studies that passed the inclusion criteria. All coordinates were converted to MNI standard space (using the Brett transform as implemented in the tal2mni/mni2tal function of MATLAB (R2020a, Mathworks, United States). It is important to note that all MRI studies included placebo (control) groups and the data reported are comparisons of drug vs placebo effects.
Additionally, all the available PET studies (with different tracers) are discussed in a narrative manner, given the insight they provide on molecular mechanisms of action.

ALE Analysis
ALE meta-analysis was carried out as described previously by (Turkeltaub et al., 2002). To assess the statistical significance of the results we used a permutation test (1,000 permutations) and set a threshold p value < 0.001 and a minimum cluster size of 200 mm 3 (Eickhoff et al., 2016). We used GingerALE (v3.0.2), the Java version of ALE developed at the Research Imaging center and available at http://brainmap.org/ale for data processing. For visualization, the results were overlaid into a standard MNI image template (Kochunov et al., 2002).
Since we found fMRI experiments with BOLD and connectivity results, we performed an ALE including all fMRI papers and two other separate analysis: 1) using the results from the BOLD amplitude changes; 2) using the connectivity results from the fMRI papers. The resulting ALE images were converted to Z scores in order to simplify interpretation and show their significance.
Activation maps related to each of the tasks were overlaid and displayed using Mango software (http://ric.uthscsa.edu/mango/) and the Talairach Daemon (http://talairach.org/) tool was used to extract anatomical labels of results. All the input files used in our analysis and output results are freely available upon request to the corresponding author.

RESULTS
Published papers were screened for the methodological information. A total of 78 papers were initially included ( Figure 1 summarizes the number of papers and number of excluded at each stage as a flow PRISMA diagram; see Table 1). All included studies have N > 8 subjects (range 10-38 participants; Median 20, total of 323 participants for fMRI studies and 57 for PET studies). These studies included BOLD, Connectivity and PET studies. Table 1 reports the demographic information of the selected datasets, the drugs in use, experimental task and a descriptive summary of the individual results. Detailed information about the design, doses, route of administration and comparators are presented in Supplementary Table S1.  A total of 323 subjects participated in this set of Psychoactive studies that include LSD, Psilocybin, Ayahuasca and DMT. The age range of the participants was 20-60 years. In total, there were 98 foci for the BOLD studies and 76 foci in the connectivity studies that were included in the meta-analysis.
We performed quantitative ALE meta-analysis using fMRI activation data both for BOLD and connectivity reports. The individual meta-analysis of brain activation and connectivity associated with psychoactive drugs revealed eleven clusters of reliable activation and connectivity modulation across studies. Table 2 identifies the coordinates of the peak voxel of each cluster and the brain region label including statistical values. There, MNI coordinates and the ALE values of the clusters are reported. We found a set of areas that are affected by psychoactive drugs and those areas are mainly located at frontal, parietal and limbic lobes. In particular, Putamen and Anterior cingulate activations are reported with highly significant alterations (p < 0.00001).
Regarding separate BOLD and connectivity results ( Table 2), the ALE analysis shows reliable alterations (mainly deactivations) that strongly appear in the Amygdala, temporal gyrus and fusiform gyrus (p < 0.0004; Zmin 3.38) for the BOLD studies when participants receive the psychoactive drugs irrespectively of the task in hand and mainly at the right hemisphere ( Figure 2). On the other hand, connectivity studies analysis revealed a distributed network of changed connections in the left hemisphere when participants are under the effect of psychoactive drugs. This network includes particularly the cingulate cortex (Brodmann areas 31 and 32; p < 0.000013; Z 4.22) and the inferior temporal gyrus (p < 0.00002; Z 4.10) in the occipital lobe. Figure 2 depicts the brain maps of concordant clusters of significant alterations (p < 5E-4) during psychoactive drug experiments.
Additionally, we performed a systematic review of the PET studies in the field. Surprisingly, we only found four studies that passed the inclusion criteria. These studies reported results for distinct PET tracers namely (18F) DG and (11C) Cimbi-36, only the latter being related to 5-HT2AR, a serotonin receptor for which there is wide evidence for psychoactive drug effects. Other studies have addressed the distribution of 5-HT2A receptors such (18F) altanserin (11C) Cimbi-36 or (18F) setoperone but with no direct link to the effects of hallucinogens. For example, the PET study from Stenbaek et al., 2018 in 159 participants shows that differences in 5-HT2AR availability are not related to variations in trait Openness in healthy individuals, which is at odds with the notion that putative stimulation of the 5-HT2AR with compounds such as psilocybin may contribute to long-term changes in trait Openness. This study, which was not formally included because psilocybin or other hallucinogens were not administered, shows that in any case there is no evidence in favor of an association between 5-HT2AR and trait Openness, ruling out a simple link between this trait and 5-HT2AR effects of psylocibin. This concept that neural effects stem mainly from 5-HT2AR has been challenged for indoleamine/tryptamine hallucinogens. A large body of evidence demonstrates indeed that both 5-HT1A and 5-HT2A receptors are responsible for the behavioral effects of these hallucinogens (Halberstadt and Geyer, 2011). These authors point out that, in general, different neurotransmitter systems contribute to the effects of indoleamine/tryptamine hallucinogens, which in the case of LSD involves also dopamine receptors.
Contrary to the MRI studies that report effects of using several distinct hallucinogenic drugs, the PET studies focused on the effects of the Psilocybin. These molecular studies reveal distinct 5-HT2AR receptor occupancy and density as a consequence of Psilocybin intake (Madsen et al., 2021). There was a decrease in receptor binding particularly in frontal regions. While this confirms the action of Psilocybin at the level of these receptors it does not preclude actions in other neurotransmitter systems. Accordingly, Psilocybin significantly decreased [11 C]raclopride receptor binding potential (BP) bilaterally in the caudate nucleus and putamen (Vollenweider et al., 1999) showing that effects are not at all exclusive to the 5-HT2AR system, but include the D2 dopamine receptor.
Concerning 18-FDG studies, Vollenweider et al. (1997) suggested that Psilocybin induced "metabolic hyperfrontaly", as encountered in baseline states of psychosis. Using the same radiotracer, Gouzoulis-Mayfrank et al. (1999) partially replicated these findings by showing that psilocybin increased metabolism in distinct right hemispheric frontotemporal cortical regions, particularly in the anterior cingulate, in contrast with the thalamus. More placebo controlled molecular imaging studies are needed to understand the impact of tryptamine hallucinogens in the brain. Nevertheless, molecular imaging atlas of different 5-HT receptor systems (Beliveau et al., 2017) suggest that the regions found in most fMRI studies share a sizable density of both 5-HT1A and 5-HT2A receptors.

Psychological Effects
The profound experience induced by psychedelics like DMT, Ayahuasca, LSD and Psilocybin is characterized by changes in emotion, perception and cognition, visual imagery and differences in the sense of self (Swanson, 2018;Barrett et al., 2020b;Lowe et al., 2021;Luppi et al., 2021). Figure 3 summarizes these effects.

Amygdala and Emotional Effects and Anxiety
The most obvious finding of our analysis is the deactivation of the amygdala during the psychedelic induced states, which might FIGURE 2 | Brain activation maps for tryptamine psychedelics studies. An extended network shows up in the quantitative meta-analysis. Frontal decision related areas and other visuo-temporal areas are affected by the drug. Particularly, right amygdala is implicated in the effects of the psychedelics drugs. These results are significant at p < 0.0001. underlie the emotional effects of these substances. Altered processing of facial expressions with negative valence and modulation of the amygdala activity to these stimuli has been found after the administration of serotonergic psychedelics on healthy and clinical populations (Rocha et al., 2019). The decreased reactivity of the amygdala to negative stimuli was also associated with an increase of positive mood states during the acute phase (Kraehenmann et al., 2015) and also long-term (Barrett et al., 2020). These effects may be of clinical relevance in disorders associated with difficulties in emotional processing such as depression, anxiety and addiction. Previous studies evaluating anxiety disorders have found consistent findings on the role of the amygdala in the symptoms of fear and anxiety (Holzschneider and Mulert, 2011). Meta-analytic evidence revealed consistent hyperactivation of the amygdala in post-traumatic stress disorder, social anxiety disorder and specific phobia, as well as during fear conditioning in healthy subjects, suggesting a common excessive engagement of fear circuitry (Etkin and Wager, 2007). Our results also show a greater deactivation in the right amygdala. Although there are no conclusive findings on the lateralization of amygdala in emotional processing (Kraehenmann et al., 2015), some studies point to different activations. During the presentation of emotional stimulus, right amygdala hyperactivation was observed in patients with PTSD compared with traumaexposed non-PTSD individuals (Brohawn et al., 2010), as well as in patients with obsessive-compulsive disorder compared with healthy controls (Thorsen et al., 2018). In the latter, right amygdala hyperactivation was more evident in unmedicated patients. An increased influence from right amygdala to right middle frontal gyrus and a decreased influence from right precuneus to right amygdala was also associated to the trait neuroticism, which is the tendency to experience negative emotional states and negative self-referential information processing (Pang et al., 2016). Further research should be undertaken to elucidate the long-term impact of psychedelics on amygdala responsiveness. Recent findings from healthy populations indicated a reduced amygdala response to facial stimuli 1-week post-psilocybin, returning to baseline after 1 month (Barrett et al., 2020). Nevertheless, an increased reactivity was found in clinical populations 1 day after psilocybin session (Roseman et al., 2018).

Salience Network and Pain, Psychiatric and Neurological Disorders
Another important finding was the deactivation of brain areas associated with the Salience Network (SN), such as the dorsal anterior cingulate cortex. This network is involved in attributing salience and selecting relevant interoceptive, autonomic and emotional stimuli (Menon, 2015). Dysfunctions on salienceprocessing are relevant in many psychiatric and neurological disorders, such as schizophrenia, dementia, autism, mood and anxiety disorders, drug addiction and pain (Menon, 2015;Uddin, 2015). An aberrant salience attribution to internal stimuli is proposed as a model for psychosis (Kapur, 2003), and is also conceptualized as having an important role in the symptoms of delusions and hallucinations in schizophrenia (Palaniyappan and Liddle, 2012). These findings may help to understand the early research on psychedelics as models for psychosis. A salience network dysfunction hypothesis is also considered in autism spectrum disorder, which suggests that impaired attribution to sensory stimuli might be associated with dysfunctional cognitive processes, such as social cognition (Uddin, 2015).

Theory of Mind and Social Cognition
We also found relevant patterns in regions involved in theory of mind such as supramarginal gyrus, medial prefrontal cortex, precuneus and posterior cingulate cortex. LSD decreased the efficiency of establishing joint attention in the PCC and the temporal gyrus, an effect attributed to 5-HT2AR stimulation (Preller et al., 2018). The authors suggested a decreased differentiation between the self and the other during social interactions. This altered sense of self characterized by a decreased differentiation between self-representations and other-representations is usually called "ego dissolution" (Nour et al., 2016). In addition, psilocybin decreased the feeling of social exclusion processing in the ACC . These findings point to the modulation of social cognition, which may be an important mechanism contributing to the therapeutic potential of psychedelics (Preller and Vollenweider, 2019). There is evidence for the role of the supramarginal gyrus, highlighted in our analysis, in overcoming emotional egocentricity bias in social judgements Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 739053 (Silani et al., 2013), which suggests a possible role in empathy. The overlap between some areas involved in theory of mind and the default mode network (DMN) has led some authors to suggest the role of the DMN in the social understanding of others (Li et al., 2014), as well as the role of the PCC in attributing mental states to others (Mars et al., 2012). Tagliazucchi et al. (2016) reported that LSD-induced states increased functional connectivity in bilateral temporo-parietal junction, a key component of theory of mind, which was correlated to subjective reports of ego dissolution. In line with this, previous studies indicated the effects of tryptamine psychedelics on dimensions related to healthy social functioning such as increased emotional empathy and prosocial behaviour (Dolder et al., 2016;Pokorny et al., 2017;Mason et al., 2019;Uthaug et al., 2021), changes in personality traits agreeableness (Netzband et al., 2020) and compassion (Apud Peláez, 2020), as well as feelings of connection to others (Watts et al., 2017). A recent study in mice reported that repeated administration of low doses of LSD promoted social behaviour by potentiating 5-HT2AR and AMPA receptor neurotransmission in the mPFC via an increasing phosphorylation of the mTORC1 (de Gregorio et al., 2021).

Mental Imagery
The activation of visual areas by psychedelics induced substances, was another outcome of our quantitative metaanalysis, namely visual areas BA19 and visual fusiform region BA37. These areas are densely populated with 5-HT2A receptors. Various studies indicated a key function for 5-HT2ARs in visual processes and the pathogenesis of visual hallucinations (Moreau et al., 2010;Seillier et al., 2017). Classical hallucinogens are used as models for studying the pathophysiology of different neuropsychiatric conditions with positive psychotic symptoms, such as schizophrenia, Parkinson's and Alzheimer's disease, which alter individual visual and perceptual experiences. The activation of 5-HT2ARs increases the excitability of the visual cortex in the absence of external visual stimulation (Moreau et al., 2010). In addition, the activation of 5-HT2ARs mediates the visual hallucinations that are generated by serotonergic hallucinogens, such as LSD or psilocybin (Nichols, 2004;Vollenweider and Kometer, 2010). In line with this, the hallucinogen-induced decrease in alpha oscillations might allow spontaneous self-organized activity to gain perceptual quality (Kometer et al., 2013). Recent studies demonstrated that acute LSD administration to healthy subjects not only produces elementary and complex visual (pseudo) hallucinations and perceptual illusions (Carhart-Harris et al., 2016b;Preller et al., 2017;Schmid et al., 2015;Schmidt et al., 2018), but also impaired inhibitory processes (Schmid et al., 2015) and cognitive organization (Carhart-Harris et al., 2016a). Impairments in inhibition after psilocybin administration and cognitive impairments after LSD administration were attenuated by administration of the 5-HT2AR antagonist ketanserin (Quednow et al., 2012;Preller et al., 2017). However, this does not exclude the contribution of other receptor subtypes such as 5-HT1AR (Halberstadt and Geyer, 2011). 5-HT2AR activation is indeed pivotal in inducing visual hallucinations but other receptors also contribute to cognitive impairments, and their abnormal activity can be associated with cognitive deficits in neuropsychiatric disorders such as schizophrenia and Alzheimer's disease (Švob Štrac et al. 2016). Schmidt et al. (2018) proposes that psychedelics disrupt information processing in inhibitory cortico-striatothalamocortical (CSTC) feedback loops that have been implicated in sensory gating of internal and external information to the cortex. This psychedelic-induced disinhibition might lead to an inability to filter and inhibit exteroceptive and interoceptive stimuli, resulting in high-level processing overload and the formation of hallucinations.
In line with our results, De Araujo et al. (2012) investigated the neuronal mechanisms underlying psychedelic-induced visual mental imagery using functional magnetic resonance imaging (fMRI). The authors found that ayahuasca increased activations in mental imagery networks, including early visual areas (BA 17,18,19), parahippocampal gyrus, middle temporal cortex, and frontal cortex (BA10). They also showed that ayahuasca-induced changes in primary visual cortex (BA17) were preceding activation patterns in higher-level areas, indicating that ayahuasca-induced imagery is initiated in BA17, but activity is spread to higher-level cortical areas involved with episodic memory retrieval and the processing of contextual associations, such as BA30 and BA37, which might feed memory-related content. In addition to perceptual alterations of simple and elementary visual features as color, brightness, visual contrast (Klüver, 1942;Rummele and Gnirss, 1961;Kometer et al., 2013;Kometer and Vollenweider, 2018) that might be explained by increased excitation in V1 (Kometer et al., 2013;Császár-Nagy et al., 2019), complex imagery and hallucinations has been reported (Császár-Nagy et al., 2019;Díaz, 2010;dos Santos et al., 2016;Kraehenmann, 2017;Kometer et al., 2013), with personal and profound significance, stemming from autobiographical memory (Studerus et al., 2011) to current life situations (Shanon, 2010) charged with emotional content. These complex forms of hallucinogen-induced hallucination and visions, also lead the recruitment of higher level regions in the brain, given that psychedelic imagery is usually very structured, thematic and personal (Kraehenmann, 2017). In accordance to our main results, studies have reported visual hallucinations caused by neuronal stimulation of PFC (Blanke et al., 2000), temporal areas (Mégevand et al., 2014;Aminoff et al., 2016) and increased functional connectivity between PFC and primary visual cortex (Carhart-Harris et al., 2016b). Furthermore, the review conducted by dos , suggested that hallucinogens increase introspection and positive mood by modulating brain activity in the fronto-temporo-parietooccipital cortices. Neuromodulatory changes induced by tryptamine psychedelics can give significant input to the study of neuropsychiatric conditions where similar patterns of activation or connectivity (Barrett et al., 2020b;Madsen et al., 2021) are found and to the implementation of new pharmacological or psychotherapeutic interventions taking advantage of this link between visual imagery, autobiographical memory and emotions (Barrett et al., 2020). The role of amygdala in this interplay is not of less importance. The amygdala plays an important role in emotional visual processing (Vuilleumier et al., 2004). Important networks between amygdala and ventral visual pathways in primates are reported (Freese and Amaral, 2005), as well as the role of the amygdala in visual awareness (Duncan and Barrett, 2007). Furl et al., 2013 suggested that the amygdala modulates visual processing by feedback connections and that it may have a contextual role during visual coding. Deactivation of the amygdala during the psychedelic induced states has been consistently found and along with the inhibition of DMN opens a therapeutic potential for accessing and transforming autobiographical memories, emotions and maladaptive perceptions.

Default Mode Network
In addition to the mechanisms described above, changes in Default Mode Network (DMN) connectivity may be another neural basis involved in the psychologic and therapeutic effects attributed to tryptamine psychedelics. DMN areas present lower levels of activity when individuals are engaged in a task requiring externally oriented attention and activate during passive rest states or internally oriented mental processes, such as autobiographical memory, mind wandering, self-reflective thought, and future thinking (Buckner et al., 2008;Andrews-Hanna et al., 2010).
In our analysis, a decreased connectivity within PCC/Precuneus, key components of the DMN, was observed. Regarding classic hallucinogens, studies revealed that psilocybin, LSD, and ayahuasca could decrease DMN functional integrity (Carhart-Harris et al., 2012, Carhart-Harris et al., 2016cPalhano-Fontes et al., 2015;Luppi et al., 2021;Madsen et al., 2021;Mason et al., 2021),. Barrett et al. (2020b), recently proposed that Psilocybin alters default mode network integrity and fronto-parietal network modularity by reducing Claustrum functional connectivity with these circuits. This study showed that psilocybin reduced activity of left and right claustrum during the acute effects of psilocybin, leading to alterations in claustrum connectivity with brain networks that support both sensory and high-level cognitive processes. Specifically, the authors found decreased connectivity between claustrum and the DMN during the effects of psilocybin, decreased connectivity between left claustrum and fronto-parietal task control circuits and increased connectivity between right claustrum and the same fronto-parietal networks. In sum they assigned to the claustrum (dense in 5-HT 2A receptors ) a role in the psilocybin-induced disruption in both the DMN and taskpositive networks. Accordingly, Madsen et al. (2021) found negative correlations between the DMN integrity and the plasma psilocin levels and subjective drug intensity. These results support the proposed theory of action for psychedelics to decrease the control of top-down structures and increase the excitability of areas involved in sensory, emotional and cognitive appraisal processes. (Barrett et al., 2020b;Mason et al., 2021). The expression and awareness of normally repressed information would explain the novelty of the experience and the new associations would facilitate the formation of new insights (Domínguez-Clavé et al., 2016;McKenna and Riba, 2018). In line with this, Mason et al. (2021) reported psilocybininduced decreased within-network connectivity of the DMN and increased functional connectivity between the DMN and the Frontoparietal Network (FPN) and between the DMN and the Salience Network (SN), which predicted higher scores in aspects of creative thinking and long-term increases in novelty of generated ideas. However, in contrast to these findings, there have also been findings of increased DMN activity by hallucinogens Kometer et al., 2015;Petri et al., 2014;Tagliazucchi et al., 2014). Regarding the associated therapeutic potential, DMN activity is increased in depression (Sheline et al., 2009) acute and chronic pain (Alshelh et al., 2018), schizophrenia (Garrity et al., 2007) and Parkinson's disease (Van Eimeren et al., 2009) Aberrant patterns of connectivity are also found in drug addiction (Zhang and Volkow, 2019) and eating disorders (Stopyra et al., 2019). It seems to be reduced in autism and in Alzheimer's disease (Broyd et al., 2009).

Linking Molecular Imaging and Functional Magnetic Resonance Imaging Data
There were surprisingly few eligible pharmacoimaging studies using PET. Two used FDG (Vollenweider et al., 1997;Gouzoulis-Mayfrank et al., 1999) and together suggested frontal and temporal hypermetabolism, which are consistent with fMRI data. Another used the 5-HT2AR agonist radioligand (11C) Cimbi-36, and showed that intake of psilocybin leads to significantly 5-HT2AR reduced occupancy in the human brain, confirming a role for this receptor subtype. However, a specific link with this receptor system is probably an overstatement, given the evidence that multiple receptors, in particular the 5-HT1AR contribute to the behavioral effects of indoleamine hallucinogens (Halberstadt and Geyer, 2011). The neural effects of these hallucinogens seem to include regions rich in both 5-HT1AR and 5-HT2AR. These probably interact with other receptor systems such as DR2 (Vollenweider et al., 1999), whose binding is decreased probably due to endogenous dopamine release.

Therapeutic Potential
Taken together, our results support the plausibility of further research on the therapeutic potential of tryptamine psychedelics (Lowe et al., 2021). There is a growing number of clinical trials describing promising data on safety and efficacy of psychedelics and entactogens in several psychiatric disorders, such as posttraumatic stress disorder (Mitchell et al., 2021), treatmentresistant depression (Carhart-Harris et al., 2016a;Palhano-Fontes et al., 2019), substance addictions (Johnson et al., 2014;Bogenschutz et al., 2015); obsessive-compulsive disorder (Moreno et al., 2006); anxiety associated with life-threatening diseases (Gasser et al., 2014;Griffiths et al., 2016;Ross et al., 2016) and social anxiety in autistic adults (Danforth et al., 2018). Those preliminary findings suggest the reduction of depressant, anxiety and addiction symptoms. Patients described feelings of connection, transcendence, insights, self-awareness, alterations in the perception of the self, emotional catharsis, changes in values and life orientations, reconciliations with death, as well as psychological distress Schmid et al., 2015;Belser et al., 2017;Swift et al., 2017;Watts et al., 2017;Noorani et al., 2018;Barone et al., 2019;Lowe et al., 2021), encouraging further studies. Recently, the role of psychedelics in changing behaviours related to healthy lifestyles (Teixeira et al., 2021), as well as a treatment for neurodegenerative disorders (Vann Jones and O'Kelly, 2020) and for pain conditions (Castellanos et al., 2020) has also been hypothesized. Despite the promising results, further work is required to better understand the neurobiological and psychological mechanisms of action and the potential risks underlying the therapeutic action of tryptamine psychedelics. Several questions regarding the long-term impact of psychedelics remain unanswered at the moment. Rigorous research (possibly integrating PET with fMRI (Cumming et al., 2021)) is needed, taking into account the best clinical practices.

LIMITATIONS
A limitation of our analysis is the inclusion of a few studies with relatively small sample sizes, unequal gender distribution and a minority of studies with no control group (this is the case for three PET and two MRI studies). It is nevertheless important to note that all studies included placebo control groups and the data reported are comparisons of drugs vs placebo effects (see Supplementary Table S1). Another caveat is the different substances and doses used, knowing they act on a different range of receptors. The limited number of regions included in the definition of dynamical states in some studies, is also an aspect that should be addressed in future studies.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.